Holen Sie sich die Stockscreener-App
13.62
2.42%
-0.355
Schlusskurs vom Vortag:
$13.98
Offen:
$13.9
24-Stunden-Volumen:
170.88K
Relative Volume:
0.40
Marktkapitalisierung:
$174.24M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-121.02M
KGV:
-1.21
EPS:
-11.26
Netto-Cashflow:
$-114.09M
1W Leistung:
-5.47%
1M Leistung:
-8.75%
6M Leistung:
-48.60%
1J Leistung:
+24.46%
1-Tages-Spanne:
$13.52
$14.11
1-Wochen-Bereich:
$13.16
$14.44
52-Wochen-Spanne:
$10.80
$69.97
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Firmenname
Tonix Pharmaceuticals Holding Corp
Sektor
Branche
Telefon
212-980-9155
Adresse
26 MAIN STREET, SUITE 101, CHATHAM, NY
Compare TNXP vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
13.62 | 178.78M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.36 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
765.45 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
724.67 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.19 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.66 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-04-18 | Eingeleitet | Noble Capital Markets | Outperform |
| 2019-04-18 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2017-08-18 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2016-09-07 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-02-17 | Bestätigt | Oppenheimer | Outperform |
| 2015-11-04 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-06-12 | Eingeleitet | Oppenheimer | Outperform |
| 2015-02-17 | Bestätigt | ROTH Capital | Buy |
| 2014-09-29 | Bestätigt | ROTH Capital | Buy |
Alle ansehen
Tonix Pharmaceuticals Holding Corp Aktie (TNXP) Neueste Nachrichten
Tonix Pharmaceuticals: Tonmya launches for fibromyalgia as pipeline advances toward key 2027 milestones - TradingView
Tonix Pharmaceuticals to Present Poster on Tonmya at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting - Bitget
New fibromyalgia treatment Tonmya shows gains in patient outcomes poster - Stock Titan
Tonix Pharma Uplists to Nasdaq Global Select Market - TipRanks
Tonix Pharmaceuticals announces uplisting from Nasdaq Capital Market to Nasdaq Global Select Market - marketscreener.com
Tonix Pharmaceuticals Moves Listing to Nasdaq Global Select Market - marketscreener.com
Tonix Pharmaceuticals (TNXP) Moves to Nasdaq Global Select Marke - GuruFocus
Tonix Pharmaceuticals moves to Nasdaq Global Select Market - Investing.com
Tonix Pharmaceuticals approved to transfer listing to Nasdaq Global Select Market - TradingView
Tonix Pharmaceuticals (NASDAQ: TNXP) uplists to Nasdaq Global Select tier - Stock Titan
Biotech Tonix joins Nasdaq’s top tier, which may boost visibility - Stock Titan
Avoiding Lag: Real-Time Signals in (TNXP) Movement - Stock Traders Daily
Tonix Pharmaceuticals to Present Clinical Trial Data on Fibromyalgia Drug Tonmya at 2026 AAPM PainConnect Meeting - geneonline.com
Tonix Pharmaceuticals : March 2026 Investor Deck - marketscreener.com
Tonix Pharmaceuticals to Participate in Two Investor Conferences in March - Sahm
TNXP Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Tonix (TNXP) COO awarded two stock option grants under 2020 plan - Stock Titan
Tonix (TNXP) CFO granted stock options with multi-year vesting - Stock Titan
Tonix Pharmaceuticals (TNXP) CMO granted two new stock option awards - Stock Titan
Tonix Pharmaceuticals (TNXP) CTO receives two new stock option grants - Stock Titan
Tonix Pharmaceuticals (TNXP) CEO awarded new multi-year stock option grants - Stock Titan
TNXP Stock Price, Forecast & Analysis | TONIX PHARMACEUTICALS HOLDIN (NASDAQ:TNXP) - ChartMill
Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences in March 2026 - Quiver Quantitative
Fibromyalgia drug maker Tonix to brief investors at March conferences - Stock Titan
Tonix Pharmaceuticals: Financial Runway and Pipeline Progress Under Scrutiny - AD HOC NEWS
Discipline and Rules-Based Execution in TNXP Response - Stock Traders Daily
Is Tonix Pharmaceuticals Holding Corp. forming a breakout pattern2025 Breakouts & Breakdowns & Weekly Watchlist of Top Performers - mfd.ru
Aug Catalysts: Will Tonix Pharmaceuticals Holding Corp announce a stock split2025 Technical Patterns & Daily Volume Surge Trade Alerts - baoquankhu1.vn
What is the PEG ratio of Tonix Pharmaceuticals Holding Corp.2025 Volatility Report & Accurate Entry and Exit Point Alerts - mfd.ru
TNXP PE Ratio & Valuation, Is TNXP Overvalued - Intellectia AI
What are Tonix Pharmaceuticals Holding Corp.’s earnings expectationsSwing Trade & Community Trade Idea Sharing Platform - mfd.ru
TNXP News Today | Why did Tonix Pharmaceuticals stock go up today? - MarketBeat
Behavioral Patterns of TNXP and Institutional Flows - Stock Traders Daily
Market Recap: Will Tonix Pharmaceuticals Holding Corp stock benefit from M APortfolio Value Report & Safe Capital Growth Stock Tips - baoquankhu1.vn
Earnings Recap: Can Tonix Pharmaceuticals Holding Corp deliver alphaJuly 2025 Opening Moves & Verified Momentum Stock Ideas - baoquankhu1.vn
Dying for Some Sleep - RealClearHealth
Tonix Pharmaceuticals (TNXP) outlines preliminary 2025 figures and cash runway into 2027 - Stock Titan
Tonix opens Berkeley Heights HQ, expands NJ biotech footprint - NJBIZ
Aug Opening: How volatile is Haverty Furniture Companies Inc stockPortfolio Risk Report & Verified High Yield Trade Plans - baoquankhu1.vn
Tonix’s fibromyalgia drug shows significant pain reduction in study By Investing.com - Investing.com Australia
Tonix Highlights Significant Phase 3 RESILIENT Results For TONMYA At Non-Opioid Pain Summit - Nasdaq
Tonix Presents Positive Phase 3 RESILIENT Data On TONMYA At 2026 Non-Opioid Pain Therapeutics Summit - Nasdaq
Tonix Pharmaceuticals (TNXP) Reports Positive Phase 3 Trial Resu - GuruFocus
Tonix’s fibromyalgia drug shows significant pain reduction in study - Investing.com
Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit - The Manila Times
Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on - GlobeNewswire
Pharma company Tonix opening HQ in Berkeley Heights - ROI-NJ
Fibromyalgia Market: Expanding Revenue Landscape to 2034 – DelveInsight | UCB Pharma, Eli Lilly and Company, Merck, Aptinyx, Astellas Pharma, Tonix Pharma, UCB Biopharma SRL, GSK, UCB Pharma - Barchart.com
(TNXP) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
A. G. P. Maintains Tonix Pharmaceuticals(TNXP.US) With Buy Rating, Maintains Target Price $65 - 富途牛牛
Trend Review: Is now the right time to enter Tonix Pharmaceuticals Holding CorpEarnings Overview Report & High Return Trade Guides - baoquankhu1.vn
Finanzdaten der Tonix Pharmaceuticals Holding Corp-Aktie (TNXP)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):